Pharmacogenetics of lithium response

Psychiatric Annals

Volumn 38, Issue 6, 2008, Pages 401-407

  Cruceanu, Cristiana ^a   De Lara, Catalina Lopez ^a   Alda, Martin ^b   Turecki, Gustavo ^a  

^a DOUGLAS MENTAL HEALTH UNIVERSITY INSTITUTE   (Canada)

^b DALHOUSIE UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 47649092504     PISSN: 00485713     EISSN: None     Source Type: Journal    
DOI: 10.3928/00485713-20080601-09     Document Type: Review

References (76)

1. Lenox RH, Watson DG. Lithium and the brain: a psychopharmacological strategy to a molecular basis for manic depressive illness. Clin Chem. 1994;40(2):309-314.
2. Schou M. Preventive lithium treatment in manic-depressive disease: experiences and progress in recent years. Nervenarzt. 1983;54(7):331-339.
3. Mamdani F, Groisman IJ, Alda M, Turecki G. Pharmacogenetics and bipolar disorder. Pharmacogenomics J. 2004;4(3):161-170.
4. Ruzickova M, Turecki G, Alda M. Pharmacogenetics and mood stabilization in bipolar disorder. Am J Med Genet C Semin Med Genet. 2003;123(1):18-25.
5. Grof P, Alda M, Grof E, Fox D, Cameron P. The challenge of predicting response to stabilising lithium treatment. The importance of patient selection. Br J Psychiatry Suppl. 1993(21):16-19.
6. Goldberg JF, Garno JL, Leon AC, Kocsis JH, Portera L. A history of substance abuse complicates remission from acute mania in bipolar disorder. J Clin Psychiatry. 1999;60(11):733-740.
7. Greil W, Kleindienst N, Erazo N, Müller-Oerlinghausen B. Differential response to lithium and carbamazepine in the prophylaxis of bipolar disorder. J Clin Psychopharmacol. 1998;18(6):455-460.
8. Kusalic M, Engelsmann F. Predictors of lithium treatment responsiveness in bipolar patients. A two-year prospective study. Neuropsychobiology. 1998;37(3):146-149.
9. Grof P. Mood disorders - new definitions, treatment directions, and understanding. Can J Psychiatry. 2002;47(2):123-124.
10. Calabrese JR, Fatemi SH, Kujawa M, Woyshville MJ. Predictors of response to mood stabilizers. J Clin Psychopharmacol. 1996;16(2 Suppl 1):24S-31S.
11. Bowden CL. Clinical correlates of therapeutic response in bipolar disorder. J Affect Disord. 2001;67(1-3):257-265.
12. Grof P, Alda M, Grof E, Zvolsky P, Walsh M. Lithium response and genetics of affective disorders. J Affect Disord. 1994;32(2):85-95.
13. Alda M. Bipolar disorder: from families to genes. Can J Psychiatry. 1997;42(4):378-387.
14. Passmore MJ, Garnham J, Duffy A, et al. Phenotypic spectra of bipolar disorder in responders to lithium versus lamotrigine. Bipolar Disord. 2003;5(2):110-114.
15. Dunner DL, Fleiss JL, Fieve RR. Lithium carbonate prophylaxis failure. Br J Psychiatry. 1976;129:40-44.
16. Strober M, Morrell W, Burroughs J, Lampert C, Danforth H, Freeman R. A family study of bipolar I disorder in adolescence. Early onset of symptoms linked to increased familial loading and lithium resistance. J Affect Disord. 1988;15(3):255-268.
17. Engstrom C, Aström M, Nordqvist-Karlsson B, Adolfsson R, Nylander PO. Relationship between prophylactic effect of lithium therapy and family history of affective disorders. Biol Psychiatry. 1997;42(6):425-433.
18. Coryell W, Akiskal H, Leon AC, Turvey C, Solomon D, Endicott J. Family history and symptom levels during treatment for bipolar I affective disorder. Biol Psychiatry. 2000;47(12):1034-1042.
19. Mendlewicz J, Fieve RR, Stallone F. Relationship between the effectiveness of lithium therapy and family history. Am J Psychiatry. 1973;130(9):1011-1013.
20. Prien RF, Caffey EM, Klett CJ. Factors associated with treatment success in lithium carbonate prophylaxis. Report of the Veterans Administration and National Institute of Mental Health collaborative study group. Arch Gen Psychiatry. 1974;31(2):189-192.
21. Smeraldi E, Petroccione A, Gasperini M, Macciardi F, Orsini A, Kidd KK. Outcomes on lithium treatment as a tool for genetic studies in affective disorders. J Affect Disord. 1984;6(2):139-151.
22. Turecki G, Grof P, Grof E, et al. Mapping susceptibility genes for bipolar disorder: a pharmacogenetic approach based on excellent response to lithium. Mol Psychiatry. 2001;6(5):570-578.
23. Grof P, Duffy A, Kutcher S, et al. Is response to prophylactic lithium a familial trait? J Clin Psychiatry. 2002;63(10):942-947.
24. Alda M, Grof E, Cavazzoni P, et al. Autosomal recessive inheritance of affective disorders in families of responders to lithium prophylaxis? J Affect Disord. 1997;44(2-3):153-157.
25. Alda M, Grof P, Grof E, Zvolsky P, Walsh M. Mode of inheritance in families of patients with lithium-responsive affective disorders. Acta Psychiatr Scand. 1994;90(4):304-310.
26. Soares JC, Gershon S. The lithium ion: a foundation for psychopharmacological specificity. Neuropsychopharmacology. 1998;19(3):167-182.
27. Post RM, Uhde TW, Roy-Byrne PP, Joffe RT. Correlates of antimanic response to carbamazepine. Psychiatry Res. 1987;21(1):71-83.
28. Swann AC, Bowden CL, Morris D, et al. Depression during mania. Treatment response to lithium or divalproex. Arch Gen Psychiatry. 1997;54(1):37-42.
29. Duffy A, Alda M, Kutcher S, et al. A prospective study of the offspring of bipolar parents responsive and nonresponsive to lithium treatment. J Clin Psychiatry. 2002;63(12):1171-1178.
30. Demidenko N, Grof P, Alda M, Deshauer D, Duffy A. MMPI as a measure of subthreshold and residual psychopathology among the offspring of lithium responsive and non-responsive bipolar parents. Bipolar Disord. 2004;6(4):323-328.
31. Duffy A, Alda M, Milin R, Grof P. A consecutive series of treated affected offspring of parents with bipolar disorder: is response associated with the clinical profile? Can J Psychiatry. 2007;52(6):369-376.
32. Duffy A, Alda M, Crawford L, Milin R, Grof P. The early manifestations of bipolar disorder: a longitudinal prospective study of the offspring of bipolar parents. Bipolar Disord. 2007;9(8):828-838.
33. Kruger S, Alda M, Young LT, Goldapple K, Parikh S, Mayberg HS. Risk and resilience markers in bipolar disorder: brain responses to emotional challenge in bipolar patients and their healthy siblings. Am J Psychiatry. 2006;163(2):257-264.
34. Aita VM, Liu J, Knowles JA, et al. A comprehensive linkage analysis of chromosome 21q22 supports prior evidence for a putative bipolar affective disorder locus. Am J Hum Genet. 1999;64(1):210-217.
35. Blackwood DH, He L, Morris SW, et al. A locus for bipolar affective disorder on chromosome 4p. Nat Genet. 1996;12(4):427-430.
36. Ewald H, Flint T, Kruse TA, Mors O. A genome-wide scan shows significant linkage between bipolar disorder and chromosome 12q24.3 and suggestive linkage to chromosomes 1p22-21, 4p16, 6q14-22, 10q26 and 16p13.3. Mol Psychiatry. 2002;7(7):734-744.
37. Morissette J, Villeneuve A, Bordeleau L, et al. Genome-wide search for linkage of bipolar affective disorders in a very large pedigree derived from a homogeneous population in quebec points to a locus of major effect on chromosome 12q23-q24. Am J Med Genet. 1999;88(5):567-587.
38. Degn B, Lundorf MD, Wang A, et al. Further evidence for a bipolar risk gene on chromosome 12q24 suggested by investigation of haplotype sharing and allelic association in patients from the Faroe Islands. Mol Psychiatry. 2001;6(4):450-455.
39. Detera-Wadleigh SD, Badner JA, Berrettini WH, et al. A high-density genome scan detects evidence for a bipolar-disorder susceptibility locus on 13q32 and other potential loci on 1q32 and 18p11.2. Proc Natl Acad Sci U S A. 1999;96(10):5604-5609.
40. Badenhop RF, Moses MJ, Scimone A, et al. A genome screen of a large bipolar affective disorder pedigree supports evidence for a susceptibility locus on chromosome 13q. Mol Psychiatry. 2001;6(4):396-403.
41. Berrettini WH, Ferraro TN, Goldin LR, et al. Chromosome 18 DNA markers and manic-depressive illness: evidence for a susceptibility gene. Proc Natl Acad Sci U S A. 1994;91(13):5918-5921.
42. Freimer NB, Reus VI, Escamilla MA, et al. Genetic mapping using haplotype, association and linkage methods suggests a locus for severe bipolar disorder (BPI) at 18q22-q23. Nat Genet. 1996;12(4):436-441.
43. Kelsoe JR, Spence MA, Loetscher E, et al. A genome survey indicates a possible susceptibility locus for bipolar disorder on chromosome 22. Proc Natl Acad Sci U S A. 2001;98(2):585-590.
44. Badner JA, Gershon ES. Meta-analysis of whole-genome linkage scans of bipolar disorder and schizophrenia. Mol Psychiatry. 2002;7(4):405-411.
45. Segurado R, Detera-Wadleigh SD, Levinson DF, et al. Genome scan meta-analysis of schizophrenia and bipolar disorder, part III: Bipolar disorder. Am J Hum Genet. 2003;73(1):49-62.
46. Ewald H, Wang AG, Vang M, Mors O, Nyegaard M, Kruse TA. A haplotype-based study of lithium responding patients with bipolar affective disorder on the Faroe Islands. Psychiatr Genet. 1999;9(1):23-34.
47. Shink E, Morissette J, Sherrington R, Barden N. A genome-wide scan points to a susceptibility locus for bipolar disorder on chromosome 12. Mol Psychiatry. 2005;10(6):545-552.
48. Young LT, Joffe RT. Bipolar disorder: biological models and their clinical application. London: Informa Health Care; 1997.
49. Berridge MJ, Downes CP, Hanley MR. Neural and developmental actions of lithium: a unifying hypothesis. Cell. 1989;59(3):411-419.
50. Klein PS, Melton DA. A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci U S A. 1996;93(16):8455-8459.
51. Detera-Wadleigh SD. Lithium-related genetics of bipolar disorder. Ann Med. 2001;33(4):272-285.
52. Benedetti F, Bernasconi A, Lorenzi C, et al. A single nucleotide polymorphism in glycogen synthase kinase 3-beta promoter gene influences onset of illness in patients affected by bipolar disorder. Neurosci Lett. 2004;355(1-2):37-40.
53. Benedetti F, Serretti A, Pontiggia A, et al. Long-term response to lithium salts in bipolar illness is influenced by the glycogen synthase kinase 3-beta -50 T/C SNP. Neurosci Lett. 2005;376(1):51-55.
54. Szczepankiewicz A, Rybakowski JK, Suwalska A, et al. Association study of the glycogen synthase kinase-3beta gene polymorphism with prophylactic lithium response in bipolar patients. World J Biol Psychiatry. 2006;7(3):158-1561.
55. Adli M, Hollinde DL, Stamm T, et al. Response to lithium augmentation in depression is associated with the glycogen synthase kinase 3-beta -50T/C single nucleotide polymorphism. Biol Psychiatry. 2007;62(11):1295-1302.
56. Böer U, Cierny I, Krause D, et al. Chronic lithium salt treatment reduces CRE/CREB-directed gene transcription and reverses its upregulation by chronic psychosocial stress in transgenic reporter gene mice. Neuropsychopharmacology. 2007.
57. Schwaninger M, Blume R, Krüger M, Lux G, Oetjen E, Knepel W. Involvement of the Ca(2+)-dependent phosphatase calcineurin in gene transcription that is stimulated by cAMP through cAMP response elements. J Biol Chem. 1995;270(15):8860-8866.
58. Pham TA, Impey S, Storm DR, Stryker MP. CRE-mediated gene transcription in neocortical neuronal plasticity during the developmental critical period. Neuron. 1999;22(1):63-72.
59. Kovacs KA, Steullet P, Steinmann M, et al. TORC1 is a calcium- and cAMP-sensitive coincidence detector involved in hippocampal long-term synaptic plasticity. Proc Natl Acad Sci U S A. 2007;104(11):4700-4705.
60. Böer U, Eglins J, Krause D, Schnell S, Schöfl C, Knepel W. Enhancement by lithium of cAMP-induced CRE/CREB-directed gene transcription conferred by TORC on the CREB basic leucine zipper domain. Biochem J. 2007;408(1):69-77.
61. Schreiber G, Avissar S, Aulakh CS, Murphy DL. Lithium-selective alteration of the function of brain versus cardiac Gs protein. Neuropharmacology. 1990;29(11):1067-1071.
62. Bezchlibnyk Y, Young LT. The neurobiology of bipolar disorder: focus on signal transduction pathways and the regulation of gene expression. Can J Psychiatry. 2002;47(2):135-148.
63. Yildiz A, Guleryuz S, Ankerst DP, Ongur D, Renshaw PF. Protein kinase C inhibition in the treatment of mania: a double-blind, placebo-controlled trial of tamoxifen. Arch Gen Psychiatry. 2008;65(3):255-263.
64. Seelan RS, Khalyfa A, Lakshmanan J, Casanova MF, Parthasarathy RN. Deciphering the lithium transcriptome: microarray profiling of lithium-modulated gene expression in human neuronal cells. Neuroscience. 2008;151(4):1184-1197.
65. Turecki G, Grof P, Cavazzoni P, et al. Evidence for a role of phospholipase C-gamma1 in the pathogenesis of bipolar disorder. Mol Psychiatry. 1998;3(6):534-538.
66. Alda M, Grof P, Grof E. MN blood groups and bipolar disorder: evidence of genotypic association and Hardy-Weinberg disequilibrium. Biol Psychiatry. 1998;44(5):361-363.
67. Serretti A, Lilli R, Lorenzi C, Gasperini M, Smeraldi E. Tryptophan hydroxylase gene and response to lithium prophylaxis in mood disorders. J Psychiatr Res. 1999;33(5):371-377.
68. Serretti A, Lilli R, Mandelli L, Lorenzi C, Smeraldi E. Serotonin transporter gene associated with lithium prophylaxis in mood disorders. Pharmacogenomics J. 2001;1(1):71-77.
69. Sun X, Wang JF, Tseng M, Young LT. Downregulation in components of the mitochondrial electron transport chain in the postmortem frontal cortex of subjects with bipolar disorder. J Psychiatry Neurosci. 2006;31(3):189-96.
70. Baum AE, Akula N, Cabanero M, et al. A genome-wide association study implicates diacylglycerol kinase eta (DGKH) and several other genes in the etiology of bipolar disorder. Mol Psychiatry. 2008;13(2):197-207.
71. Sun X, Young LT, Wang JF, et al. Identification of lithium-regulated genes in cultured lymphoblasts of lithium responsive subjects with bipolar disorder. Neuropsychopharmacology. 2004;29(4):799-804.
72. Bosetti F, Seemann R, Bell JM, et al. Analysis of gene expression with cDNA microarrays in rat brain after 7 and 42 days of oral lithium administration. Brain Res Bull. 2002;57(2):205-209.
73. McQuillin A, Rizig M, Gurling HM. A microarray gene expression study of the molecular pharmacology of lithium carbonate on mouse brain mRNA to understand the neurobiology of mood stabilization and treatment of bipolar affective disorder. Pharmacogenet Genomics. 2007;17(8):605-617.
74. Chetcuti A, Adams LJ, Mitchell PB, Schofield PR. Microarray gene expression profiling of mouse brain mRNA in a model of lithium treatment. Psychiatr Genet. 2008;18(2):64-72.
75. Poustka AJ, Kühn A, Groth D, et al. A global view of gene expression in lithium and zinc treated sea urchin embryos: new components of gene regulatory networks. Genome Biol. 2007;8(5):R85.
76. Cipriani A, Pretty H, Hawton K, Geddes JR. Lithium in the prevention of suicidal behavior and all-cause mortality in patients with mood disorders: a systematic review of randomized trials. Am J Psychiatry. 2005;162(10):1805-1819.